Aortic Regurgitation

Aortic regurgitation (AR) is the pathological retrograde flow of blood from the aorta into the left ventricle during diastole, resulting from incompetence of the aortic valve. AR represents a significant cause of valvular heart disease in developed nations, with a prevalence of 4-10% in the general population depending on severity criteria and age group; moderate to severe AR occurs in approximately 0.5-2% of adults. The condition manifests along a spectrum from hemodynamically insignificant chronic regurgitation to acute, life-threatening valvular failure requiring emergent surgical intervention. Understanding the pathophysiology, natural history, and indications for intervention is essential for internal medicine practitioners and cardiologists, as untreated severe AR leads to progressive left ventricular dysfunction and adverse outcomes; moreover, AR frequently appears in USMLE Step 2 CK cases involving both primary valvular disease and secondary causes such as endocarditis, aortic dissection, and inflammatory conditions.

The pathophysiology of aortic regurgitation involves complex hemodynamic derangements that differ fundamentally between acute and chronic presentations, with each triggering distinct compensatory mechanisms at the molecular, cellular, and organ levels.

In acute AR (occurring over hours to days), the left ventricle faces an abrupt increase in end-diastolic volume without adequate time for compensatory hypertrophy. During diastole, blood from the aorta (driven by diastolic pressure gradient) flows retrograde across the incompetent aortic valve into an unprepared LV chamber. This sudden volume load increases LV end-diastolic pressure (LVEDP) acutely; because the LV has not undergone eccentric remodeling, increased wall stress generates elevated diastolic pressures. The elevated LVEDP is transmitted retrograde through the mitral apparatus, elevating left atrial pressure and precipitating acute pulmonary edema. Additionally, the stroke volume (which equals forward flow plus regurgitant volume) increases acutely, but the elevated impedance prevents adequate systolic ejection, leading to decreased diastolic blood pressure and reduced coronary perfusion pressure—a critical problem because increased myocardial oxygen demand from heightened wall stress confronts diminished supply. The heart operates on a disadvantageous portion of the Frank-Starling curve, with minimal further contractile reserve. Systemic perfusion becomes compromised as forward cardiac output cannot keep pace with the combined demands of regurgitation and systemic vascular resistance, potentially precipitating shock and end-organ hypoperfusion.

Chronic AR develops over months to years and triggers a fundamentally different pathophysiologic response centered on adaptive eccentric hypertrophy. The chronically increased diastolic volume load activates sarcomeric stretch-sensitive pathways, principally involving mechanoreceptors and the renin-angiotensin-aldosterone system (RAAS). Angiotensin II, through AT1 receptor stimulation, promotes myocyte elongation via addition of sarcomeres in series—the defining feature of eccentric hypertrophy—rather than the concentric (parallel) sarcomere addition seen in pressure-overload states. This eccentric remodeling increases LV chamber dimensions and mass, allowing the ventricle to accommodate the increased stroke volume at lower wall stress (Laplace's law: wall stress = pressure × radius / 2 × wall thickness; increased wall thickness partially offsets increased radius). The LV compliance curve shifts rightward and downward, permitting diastolic filling at relatively normal diastolic pressures despite massive volume overload—this is the key adaptation distinguishing chronic from acute AR.

At the cellular level, chronic AR activates oxidative stress pathways through mitochondrial dysfunction and increased reactive oxygen species (ROS) production. Myocyte apoptosis increases via activation of the intrinsic mitochondrial pathway (cytochrome c release, caspase-9 activation) and extrinsic pathways (TNF-α and Fas ligand signaling). Matrix metalloproteinases (MMPs), particularly MMP-9 and MMP-2, become upregulated through RAAS and inflammatory cytokine signaling; MMPs degrade type I and III collagen in the extracellular matrix, promoting chamber dilation and fibrosis. Fibroblasts differentiate into myofibroblasts (via TGF-β signaling) and deposit excess collagen, particularly in perivascular spaces and around myocytes, creating a restrictive environment that eventually impairs diastolic function independent of cavity size.

The compensated chronic phase maintains normal or near-normal systolic function through multiple mechanisms: (1) increased preload (via the Frank-Starling mechanism) augments contractility; (2) mild reduction in afterload (from regurgitant flow unloading) paradoxically aids systolic emptying; and (3) neurohormonal activation (sympathetic nervous system, RAAS) maintains contractility via β-adrenergic and angiotensin II signaling. However, this compensation is ultimately maladaptive over years. Progressive myocyte loss, increased afterload as systemic vascular compliance decreases with age, and accumulating fibrosis eventually overwhelm adaptive capacity, leading to a transition from the compensated to decompensated phase characterized by declining ejection fraction, elevated filling pressures, and clinical heart failure symptoms.

The severity of AR is governed by the area of the regurgitant orifice, the aortic-to-LV diastolic pressure gradient, and diastolic time period. In early diastole, the aortic diastolic pressure exceeds LV diastolic pressure, driving maximal regurgitant flow; as LV pressure rises and aortic pressure falls, the gradient narrows and regurgitant flow diminishes. In severe acute AR with rapid LVEDP rise, aortic diastolic pressure may equilibrate with LV pressure by mid-diastole, eliminating the driving gradient and paradoxically reducing flow. The rate of aortic diastolic pressure decay correlates with regurgitant severity—steep descending aortic diastolic pressure curves on arterial tracing indicate severe regurgitation.

Chronic AR increases total LV stroke volume substantially (forward stroke volume plus regurgitant volume); though forward cardiac output may be maintained, myocardial oxygen consumption rises due to increased muscle mass and contractility. The enhanced diastolic load paradoxically improves systolic performance initially through increased preload, masking underlying contractile impairment. This creates a "preload dependency" wherein systolic function appears maintained only in the presence of elevated filling pressures—a critical concept for surgical decision-making. When diastolic function becomes restrictive (through fibrosis and diastolic dysfunction), the LV can no longer accommodate volume at normal pressures, precipitating pulmonary edema and decompensation even before ejection fraction declines significantly.

Infective Endocarditis represents the most common cause of acute AR in modern practice, occurring through vegetation-induced valve destruction, perforation, or prolapse. Staphylococcus aureus (including MRSA) causes the most aggressive acute endocarditis with rapid hemodynamic collapse; streptococci and enterococci cause more indolent courses. Fungal endocarditis (Candida, Aspergillus) occurs predominantly in immunocompromised hosts and IV drug users. The classic pathology involves septic inflammation with vegetation formation at the base of the valve cusp, eroding through the cusp and creating a defect that permits regurgitation. In IV drug users, the prevalence of endocarditis has increased with opioid epidemiology; right-sided endocarditis can involve the pulmonary valve, but left-sided (aortic and mitral) involvement predominates in native valve disease among non-IVDU populations.

Bicuspid Aortic Valve is the most common congenital heart defect (affecting 1-2% of the general population) and predisposes to both aortic stenosis and regurgitation through abnormal cusp morphology and biomechanics. The valve may initially function adequately but develops incompetence through progressive cusp prolapse, fibrosis, and calcification; accelerated degeneration occurs due to abnormal flow patterns and increased mechanical stress on the two cusps. Bicuspid aortic valve frequently coexists with ascending aortic dilation, compounding hemodynamic stress.

Rheumatic Heart Disease remains a leading cause of AR globally, particularly in developing nations, though incidence has declined in developed countries. The acute inflammatory phase (acute rheumatic fever, ARF) involves molecular mimicry wherein group A streptococcal antigens cross-react with myocardial and valvular proteins (particularly tropomyosin and myosin heavy chain), triggering T-cell and B-cell autoimmunity. Chronic sequelae include valve fibrosis, retraction, and calcification; while rheumatic mitral stenosis predominates in the acute phase, AR develops insidiously over years as the aortic valve cusp retracts and becomes rigid, preventing complete closure in diastole. The combination of mitral and aortic involvement is common.

Degenerative/Calcific Valve Disease is increasingly recognized as a significant cause of AR, particularly in elderly populations. Calcification develops through processes analogous to atherosclerosis: endothelial dysfunction, lipoprotein infiltration, inflammatory cell recruitment, and osteogenic differentiation of valvular interstitial cells create nodular calcification. Risk factors include age, male sex, hypertension, chronic kidney disease (uremia promotes calcification), and elevated lipoprotein(a). The calcified nodules may prevent complete valve closure and can embolize, or structural changes in the valve architecture lead to cusp prolapse and regurgitation.

Aortic Dissection is the most dramatic cause of acute severe AR. Stanford Type A dissections (affecting the ascending aorta) frequently involve the aortic root. The dissection plane (between the intima and media) extends into or beyond the aortic root in approximately 50% of Type A dissections; as the false lumen expands, it can: (1) directly separate the valve leaflets from their commissural attachments, causing cusp malcoaptation; (2) distort the aortic root geometry, increasing the sinotubular diameter; and (3) obliterate coronary ostia. This produces severe acute AR requiring emergent surgical repair; the mortality is extremely high (1-2% per hour in the first 48 hours if untreated).

Aortic Root Dilation from multiple etiologies—systemic hypertension, atherosclerosis, chronic aortic dissection, or connective tissue disorders—causes secondary AR through cusp malcoaptation. As the aortic root (normally ~3 cm at the sinuses of Valsalva) dilates, the distance between the commissures increases; the cusps, which have fixed height, can no longer coapt completely during diastole, leading to a central regurgitant jet.

Marfan Syndrome produces aortic root dilation through fibrillin-1 mutations that impair TGF-β signaling regulation. Fibrillin-1 normally sequesters TGF-β by anchoring it to the extracellular matrix; loss of fibrillin function releases active TGF-β, which causes excessive smooth muscle proliferation and apoptosis, matrix degradation, and cystic medial necrosis (elastic fiber disruption and smooth muscle loss). The ascending aorta progressively dilates, leading to aortic regurgitation and aortic dissection risk; beta-blockers and ARBs (losartan) are used prophylactically to slow progression by inhibiting TGF-β signaling.

Ehlers-Danlos Syndrome (vascular type) involves type III collagen defects (COL3A1 mutations), producing connective tissue fragility. The vascular subtype carries high risk for aortic rupture and dissection; AR occurs through aortic root dilation and structural valve weakness.

Loeys-Dietz Syndrome involves transforming growth factor-β (TGF-β) receptor mutations (TGFBR1, TGFBR2) or SMAD signaling pathway mutations, leading to aggressive aortic and other vascular pathology. Aortic root dilation, dissection, and rupture occur at smaller aortic diameters than in Marfan syndrome.

Ankylosing Spondylitis and other Seronegative Spondyloarthropathies cause inflammation of the aortic root and valve. The pathophysiology involves infiltration of the aortic root by inflammatory cells (T lymphocytes and macrophages) and subsequent fibrosis. This results in aortic root dilation, aortic regurgitation, and conduction abnormalities (due to subaortic fibrosis affecting the conduction system). The prevalence of clinical AR in AS patients is approximately 1-10%, though subclinical aortic root involvement is more common. HLA-B27 positivity correlates with risk.

Syphilis (Tertiary) involves spirochete-mediated (Treponema pallidum) vasculitis of the ascending aorta and aortic root, causing "luetic aortitis." Although now rare in developed nations, tertiary syphilis remains a historical and global health concern. The inflammation preferentially involves the media, leading to aortic root dilation and AR; associated findings include Argyll Robertson pupil and tabes dorsalis in neurosyphilis.

Takayasu Arteritis is a large-vessel vasculitis affecting the aorta and proximal great vessels, predominantly in young women from Asia. Inflammatory infiltration causes aortic root dilation and AR; hypertension (from renal artery involvement) exacerbates the hemodynamic burden.

Giant Cell Arteritis occasionally involves the aorta in elderly patients, causing "giant cell aortitis" with aortic root inflammation, dilation, and AR.

Renal Failure and Uremia promote secondary aortic regurgitation through multiple mechanisms: (1) mineral metabolism derangement (phosphate and calcium dysregulation) accelerates valve calcification; (2) uremia activates inflammatory pathways; (3) secondary hyperparathyroidism increases circulating PTH, which promotes vascular and valve calcification; (4) anemia and uremia increase cardiac output, exacerbating hemodynamic stress on the valve. Dialysis-dependent patients show accelerated valve degeneration.

Systemic Lupus Erythematosus (SLE) can cause Libman-Sacks endocarditis, involving sterile vegetations on both surfaces of the valve (characteristic of SLE, unlike bacterial endocarditis which typically shows verrucous vegetations on the atrial surface). AR results from valve deformation and scarring; valve disease occurs in 5-10% of SLE patients clinically, though echocardiographic abnormalities are present in up to 50%.

Systemic Sclerosis (Scleroderma) involves myocardial fibrosis and can affect valvular function through fibrotic remodeling; aortic regurgitation is less common than mitral regurgitation in systemic sclerosis.

Behçet's Disease causes vasculitis affecting large vessels; aortic root involvement leads to AR.

Trauma can cause acute AR through penetrating or blunt aortic root injury, valve cusp rupture, or secondary to iatrogenic aortic root trauma during instrumentation.

Iatrogenic Causes include aortic valve damage during cardiac surgery, transcatheter aortic valve replacement (TAVR) with incomplete coverage of the aortic root, endoscopic instrumentation, or previous aortic balloon pump insertion.

Acute severe AR manifests dramatically with sudden onset of dyspnea, often progressing to acute pulmonary edema and cardiogenic shock within hours. Patients appear acutely ill, dyspneic at rest, with orthopnea and paroxysmal nocturnal dyspnea. The acute elevation in LV diastolic pressure causes retrograde transmission through the mitral apparatus and pulmonary venous system, precipitating interstitial and alveolar pulmonary edema; patients present with acute decompensated heart failure symptoms and may be in frank respiratory distress or require emergent intubation.

Hypotension and Shock Physiology: Severe acute AR markedly reduces effective forward cardiac output while producing acute volume expansion in a non-compliant LV. The combination creates profound hemodynamic instability—cardiac output falls while filling pressures rise acutely. Systemic arterial pressure may be normal or low; diastolic pressure particularly falls due to massive regurgitant flow throughout diastole, while systolic pressure may remain relatively preserved in the early phase from

The ACC/AHA stages A through D (at risk, progressive, asymptomatic severe, symptomatic severe) are the named classification examiners expect, and they, not symptoms alone, drive intervention.